| NCT ID | NCT03308474 |
| Status | Recruiting |
| Phase | — |
| Sponsor | iOMEDICO AG |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,200 participants |
| Start Date | 2017-09-25 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,200 participants in total. It began in 2017-09-25 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.
Eligibility Criteria
Inclusion Criteria: * MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment) * Age ≥ 18 years * Written informed consent * Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment * Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment * Sufficient German language skills for participation in the PRO satellite Exclusion Criteria: * No systemic therapy for myeloma * Patients already enrolled in studies that prohibit any participation in other studies
Contact & Investigator
Hermann Einsele, Prof MD
STUDY CHAIR
Wuerzburg University Hospital
Frequently Asked Questions
Who can join the NCT03308474 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03308474 currently recruiting?
Yes, NCT03308474 is actively recruiting participants. Contact the research team at info@iomedico.de for enrollment information.
Where is the NCT03308474 trial being conducted?
This trial is being conducted at Multiple Sites, Germany.
Who is sponsoring the NCT03308474 clinical trial?
NCT03308474 is sponsored by iOMEDICO AG. The principal investigator is Hermann Einsele, Prof MD at Wuerzburg University Hospital. The trial plans to enroll 2,200 participants.